Johnson & Johnson receives a positive CHMP opinion for Rybrevant® (amivantamab) in combination with chemotherapy for the first-line treatment of patients with advanced non-small cell lung cancer with activating EGFR exon 20 insertion mutations.

This positive CHMP opinion makes amivantamab a new option, and the first fully human EGFR-MET bispecific antibody, in the first-line treatment of this lung cancer.

The recommendation follows data from the phase 3 PAPILLON study, which showed that the combination of amivantamab and chemotherapy significantly improved progression-free survival in adult patients, compared with chemotherapy alone.

The results of the PAPILLON study represent an important advance in the therapeutic field of EGFR exon 20 non-small cell lung cancer, demonstrating a significant improvement in progression-free survival with amivantamab combined with first-line chemotherapy, compared with chemotherapy alone', said study investigator Professor Nicolas Girard, Head of the Medical Oncology Department at the Institut Curie and Professor of Thoracic Oncology and Respiratory Medicine at the Université Paris Saclay (France).

Copyright (c) 2024 CercleFinance.com. All rights reserved.